Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

spotitearly

Explore full profile

Develops scent based multi-cancer early detection screening test, combining bio detectors together with proprietary AI stack, to save people’s lives

Tel Aviv-Yafo, IsraelFounded 2020Biotech & Life Sciences
Valuation $100–250M Last recorded · 2025
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for spotitearly and the history behind them.

About spotitearly

Spotitearly.com is a promising startup operating in the healthcare sector, specifically in the field of cancer detection. The company is developing a groundbreaking multi-cancer early detection test that is both affordable and easy to use. The technology behind this test is designed to detect multiple types of cancer at once, including breast, lung, colon, and prostate cancer.

The company's business model is centered on the development and commercialization of this early detection test. The test is currently in the clinical trial phase, with results indicating higher sensitivity and better specificity in detecting early stages of cancer compared to existing tests on the market. This suggests that Spotitearly's product could potentially revolutionize the cancer detection market by providing a more accurate and cost-effective solution.

The company's target clients are primarily healthcare providers and patients who are at risk of developing cancer. By offering an affordable and easy-to-use test, Spotitearly aims to make early cancer detection accessible to a wider population, thereby potentially saving lives and reducing healthcare costs.

The company's revenue model is likely to be based on the sales of these tests to healthcare providers and patients. Given the high prevalence of cancer and the critical importance of early detection, the market potential for Spotitearly's product is significant.

In summary, Spotitearly is a healthcare startup focused on revolutionizing cancer detection through an innovative, affordable, and easy-to-use multi-cancer early detection test.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
Tel Aviv-Yafo, Israel
Employees
33
Open positions
None listed
Dealroom signal
75.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, medical testing
Technology
Artificial Intelligence
Business model
SaaS
Client focus
b2b

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC May 2025 $20M $81M Avishai Abrahami · Menomadin Foundation · Hanaco Venture Capital ↗
EARLY VC✓Equity / VC Nov 2023 $7.8M $31M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

spotitearly website traffic

Latest recorded traffic for spotitearly is 5.4K monthly website visits, down 12.9% over the last three months. spotitearly's team grew 3.1% over the past year.

Latest monthly visits5.4K 3-month web change-12.9% 1-year team growth+3.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Hanaco Venture Capital
  • Michael Eisenberg
  • Jeff Schwartz

Series A2 investors entered at this stage

  • Avishai Abrahami
  • Menomadin Foundation
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇮🇱 Israel65.5%
🇺🇸 United States10.3%
🇨🇾 Cyprus3.5%
🇫🇷 France3.5%
🇬🇧 United Kingdom3.5%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about spotitearly on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See spotitearly’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.